regeneron linvoseltamab

Regeneron Gets CHMP Backing of Linvoseltamab

Regeneron's linvoseltamab gets positive EU regulatory opinion

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of its drug linvoseltamab for the treatment of adults with relapsed and refractory multiple myeloma.

MarketWatch · 2d

Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy.

Business Insider · 2d

Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has

Finanznachrichten · 2d

Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human

Nasdaq2d

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Linvoseltamab is investigational and has not ... a total of two 24-hour hospitalizations for safety monitoring. About Regeneron in Hematology At Regeneron, we’re applying more than three ...

Investing2d

EMA backs Regeneron’s linvoseltamab for multiple myeloma

Linvoseltamab, which is still under investigation ... For investors tracking Regeneron’s potential in this market, InvestingPro data shows the company’s strong market position is supported ...

13d

Why Regeneron's Price May Soon Break Out

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Nasdaq2d

Regeneron: CHMP Recommends Conditional Marketing Authorization Of Linvoseltamab

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced the CHMP has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results